Do we need biomarkers for diabetics progressing to heart failure?

Do we need biomarkers for diabetics progressing to heart failure? Hellenic J Cardiol. 2018 Jun 22;: Authors: Dimitriadis K, Tsioufis C, Tousoulis D Abstract There is a cardiovascular unfavorable duet consisting of arterial hypertension and diabetes that is related with increased risk of heart failure. The latter is highly prevalent in this setting of dysregulation of glucose metabolism and high hemodynamic load and identifying predictors of incidence of heart failure with preserved ejection fraction (HFpEF) is a research and clinical need. Towards this end the variability of glucose regulation represent a novel dynamic way to comprehend and study the impact of glycemia. The results of the published study highlight the independent association of glycated hemoglobin A1c variability with the development of HFpEF in hypertensive diabetic patients. Based on the above, the effect of diverse antidiabetic therapies on glycemic control variability as well as the overall management of these patients in order to reduce the risk of HFpEF remain essential for the modern cardiologist. The growing epidemic of both diabetes mellitus and heart failure (HF) is an emerging clinical reality.1-3 The prevalence of diabetes mellitus type II has augmented from 4.7% to 8.5% in the last 25 years, whereas heart failure is currently found in 11.8% of the general population.1-4 Hypertension is closely linked to unfavorable overall cardiovascular prognosis via di...
Source: Hellenic Journal of Cardiology - Category: Cardiology Tags: Hellenic J Cardiol Source Type: research